Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.745 -0.095 (-5.16%)

Streaming Delayed Price Updated: 10:17 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

June 02, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 23, 2022

On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Lineage Cell Therapeutics: Q1 Earnings Insights ↗

May 12, 2022

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: Lineage Cell Therapeutics ↗

May 11, 2022

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

May 05, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

May 03, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

April 26, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

April 25, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

April 13, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022

April 11, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Insiders Buying These 4 Penny Stocks ↗

March 30, 2022

The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Insiders Buy Over $1.3M Of 4 Penny Stocks ↗

March 28, 2022

The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022

March 24, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss

March 21, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics's Return On Capital Employed Insights ↗

March 14, 2022

Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last...

Via Benzinga

Lineage Cell Therapeutics: Q4 Earnings Insights ↗

March 10, 2022

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement....

Via Benzinga

Lineage Cell Therapeutics's Earnings: A Preview ↗

March 09, 2022

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

March 14, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

January 24, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

January 04, 2022

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026

December 21, 2021

Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...

Via FinancialNewsMedia

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗

December 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.